NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
But Positive On Lynparza And Ibrance In Certain Settings
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
You may also be interested in...
NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.